Whereas prospective studies reported a significant correlation between serum IGF1 levels and EOC risk among women younger than 55-years (43), other studies showed decreased serum IGF1 concentrations in postmenopausal patients with ovarian tumors (44). This evidence concerns the gene IGF1 and ovarian neoplasm.